Acadian Asset Management LLC Buys New Shares in Omnicell, Inc. $OMCL

Key Points

• Acadian Asset Management acquired a new stake in Omnicell, Inc., buying 125,843 shares valued at approximately $4.39 million, representing 0.27% ownership as of the latest SEC filing.
• Recent analyst ratings for OMCL show a variety of price target adjustments, with Piper Sandler lowering its target from $57 to $55 while Wells Fargo increased its target from $37 to $40.
• Omnicell reported a 12-month high of $55.74 and a 12-month low of $22.66, with a current stock price of $31.83, down by 4.4% recently.

Acadian Asset Management LLC acquired a new position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 125,843 shares of the company's stock, valued at approximately $4,394,000. Acadian Asset Management LLC owned approximately 0.27% of Omnicell at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in OMCL. Principal Financial Group Inc. raised its stake in shares of Omnicell by 2.6% during the 1st quarter. Principal Financial Group Inc. now owns 244,644 shares of the company's stock valued at $8,553,000 after buying an additional 6,288 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Omnicell during the 1st quarter worth approximately $2,073,000. Intech Investment Management LLC lifted its holdings in Omnicell by 75.6% in the first quarter. Intech Investment Management LLC now owns 230,171 shares of the company's stock valued at $8,047,000 after acquiring an additional 99,104 shares during the last quarter. EP Wealth Advisors LLC acquired a new position in Omnicell in the first quarter valued at approximately $245,000. Finally, GSA Capital Partners LLP purchased a new stake in Omnicell in the first quarter valued at approximately $901,000. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Stock Up 1.1%

Shares of OMCL stock traded up $0.34 during trading on Thursday, reaching $31.52. The company's stock had a trading volume of 320,752 shares, compared to its average volume of 559,899. The business has a fifty day moving average price of $30.86 and a 200-day moving average price of $30.97. The company has a quick ratio of 1.24, a current ratio of 1.42 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.45 billion, a price-to-earnings ratio of 63.03, a price-to-earnings-growth ratio of 7.06 and a beta of 0.82. Omnicell, Inc. has a one year low of $22.66 and a one year high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. The company had revenue of $290.56 million for the quarter, compared to analysts' expectations of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. Omnicell's quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.51 EPS. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Insider Transactions at Omnicell

In other Omnicell news, EVP Corey J. Manley sold 3,880 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $33.25, for a total transaction of $129,010.00. Following the sale, the executive vice president directly owned 110,653 shares in the company, valued at $3,679,212.25. This represents a 3.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 2.52% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Bank of America upped their price objective on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, May 23rd. Wall Street Zen lowered shares of Omnicell from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 9th. Piper Sandler reduced their price target on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, August 11th. Finally, Wells Fargo & Company upped their price target on shares of Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research report on Monday, July 21st. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $46.71.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.